There are 2949 resources available
285P - Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis
Presenter: Fabio Marazzi
Session: E-Poster Display
Resources:
Abstract
286P - Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
Presenter: Shanu Modi
Session: E-Poster Display
Resources:
Abstract
287P - Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study
Presenter: Qingyuan Zhang
Session: E-Poster Display
Resources:
Abstract
288P - Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Presenter: David Miles
Session: E-Poster Display
Resources:
Abstract
289P - Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies
Presenter: Charles Powell
Session: E-Poster Display
Resources:
Abstract
290P - From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial
Presenter: Ornella Garrone
Session: E-Poster Display
Resources:
Abstract
291P - Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
Presenter: Jeronimo Martinez-Garcia
Session: E-Poster Display
Resources:
Abstract
292P - Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy
Presenter: Zeinab Zalat
Session: E-Poster Display
Resources:
Abstract
293P - Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases
Presenter: Thomas Bachelot
Session: E-Poster Display
Resources:
Abstract
294P - Pyrotinib and capecitabine for HER2–positive metastatic breast cancer patients with previously untreated brain metastases: A single-group multicenter phase II study
Presenter: Min Yan
Session: E-Poster Display
Resources:
Abstract